Skip to Content
MilliporeSigma
  • Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.

Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.

British journal of haematology (2014-04-24)
Ananth Shankar, Janis Hayward, Amy Kirkwood, Keith McCarthy, Martin Hewitt, Bruce Morland, Stephen Daw
ABSTRACT

The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [HL] after a primary chemotherapy alone treatment strategy. Between 2000 and 2005, 80 children with relapsed [n = 69] or primary refractory [n = 11] HL were treated on a standardized treatment protocol of 4-6 cycles of EPIC [etoposide, prednisolone, ifosfamide and cisplatin] chemotherapy. Radiotherapy was recommended to all relapsed sites. High dose therapy with stem cell rescue [SCT] was recommended for patients with poor response. The 5-year overall survival [OS] and progression-free survival from relapse was 75·8% [64·8-83·9] and 59·9% [48·3-69·7] respectively. Duration of first remission was strongly associated with OS; risk of death was decreased by 53% [Hazard ratio (HR): 0·47, 95% confidence interval (CI): 0·19-1·18] for those with a time from end of treatment to relapse of 3-12 months (compared to <3 months) and reduced by 80% (HR 0·20, 95% CI: 0·04-0·90) for those >12 months after end of treatment. Other poor prognostic factors included advanced stage disease at relapse and B symptoms at first diagnosis. The most important factor associated with salvage failure was time to relapse. Survival outcome in children with primary refractory HL is poor.

MATERIALS
Product Number
Brand
Product Description

Prednisolone, European Pharmacopoeia (EP) Reference Standard
Supelco
Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Prednisone, Pharmaceutical Secondary Standard; Certified Reference Material
Chlorambucil for system suitability, European Pharmacopoeia (EP) Reference Standard
Chlorambucil, European Pharmacopoeia (EP) Reference Standard
Bleomycin sulfate, European Pharmacopoeia (EP) Reference Standard
Cytarabine, European Pharmacopoeia (EP) Reference Standard
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
Etoposide for system suitability, European Pharmacopoeia (EP) Reference Standard
Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethasone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Epirubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Vincristine sulfate, European Pharmacopoeia (EP) Reference Standard
USP
Doxorubicin hydrochloride, United States Pharmacopeia (USP) Reference Standard
USP
Prednisone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Doxorubicin hydrochloride, 98.0-102.0% (HPLC)
Sigma-Aldrich
Chlorambucil
Sigma-Aldrich
Prednisone, ≥98%
Sigma-Aldrich
Carmustine, ≥98%
Sigma-Aldrich
cis-Diamineplatinum(II) dichloride, ≥99.9% trace metals basis
Sigma-Aldrich
Cytosine β-D-arabinofuranoside, crystalline, ≥90% (HPLC)
Sigma-Aldrich
Epirubicin hydrochloride, ≥90% (HPLC)
Sigma-Aldrich
Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)
Supelco
Prednisolone, VETRANAL®, analytical standard
Sigma-Aldrich
Vincristine sulfate, meets USP testing specifications
Sigma-Aldrich
Prednisolone, ≥99%
Sigma-Aldrich
Cytosine β-D-arabinofuranoside hydrochloride, crystalline
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, for fluorescence, mixture of bleomycin sulfate salts, lyophilized, powder or crystals, white to off-white
Sigma-Aldrich
Ifosfamide, ≥98%